Ipsen decided to temporarily pause dosing in the company’s palovarotene extension studies for patients with fibrodysplasia ossificans progressiva following a recommendation from an Independent Data Monitoring Committee.

Regeneron Pharmaceuticals Inc. said on Thursday the company’s experimental treatment for a very rare genetic bone disorder showed a nearly 90 percent reduction in new lesions compared to placebo, in a mid-stage study.